CLOs on the Move


 
ERT is a global company specializing in clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.ert.com
  • 1818, Market Street
    Philadelphia, PA USA 19103
  • Phone: 908.595.2020

Executives

Name Title Contact Details
Adam Deutsch
General Counsel and Chief Integration and Transformation Officer Profile

Similar Companies

Balance Pharmaceuticals

Balance Pharmaceuticals is a Pacific Palisades, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amplity

You knew us as PHS Health Solutions, Touchpoint, Tardis Medical, and PDI, a family of leading pharmaceutical contract commercial organizations with a reputation as a trusted partner to our clients. And we`re still all that - but now we`re Amplity Health. Our vision is singular, so we wanted our corporate identity to match. We`ve consolidated our family of brands to offer customized and multichannel medical, remote engagement, and sales solutions, along with strategic consulting and organizational capability development into one company - and with one name—Amplity. Amplity is a new pure-play pharmaceutical commercialization partner that enjoys a 35-year track record. Our client-first passion elevates, accelerates, and amplifies commercial success from product to patient.

Pulmocide

Pulmocide is a biotechnology company focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

International Stem Cell Corporation

International Stem Cell Corporation is a Oceanside, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Amolyt Pharma

Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.